A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

Who can take part

• For All Participants; Have received at least one standard therapy unless it does not exist, or available therapies are intolerable or no longer effective; For participants, who qualify for approved molecularly selected therapies such as RAS inhibitors, they must have progressed on, relapsed from, been intolerant to, ineligible, or refused those therapies
• Expansion Stage; Diagnosis of metastatic advanced UC (primary tumor: renal pelvis, ureter, urinary bladder, or urethra); At least one measurable lesion as defined by RECIST, version 1.1; Participants must be eligible for sacituzumab govitecan treatment as their next line of therapy
• At least one but no more than 3 prior lines of therapy
• Eastern Cooperative Oncology Group (ECOG) Performance Status (0-2 for monotherapy; 0-1 for combo)

Who cannot take part

• Prior anticancer treatment, including:; Radiation therapy within 2 weeks before first dose of study treatment
• Diagnosis of another cancer within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with standard therapy
• Known brain metastases or cranial epidural disease
• Current or recent severe illness
• Known history or positive test for human immunodeficiency virus (HIV) unless meets specific criteria
• Active infection with hepatitis B virus or hepatitis C virus
• Malabsorption syndrome
• History of solid organ, autologous or allogenic stem cell transplant
• Active autoimmune disease with skin involvement